Tirzepatide vs. Semaglutide for Body Recomposition: What the Clinical Data Shows
TL;DR
- On tirzepatide vs semaglutide body composition, neither drug clearly wins for muscle preservation once you account for total weight lost. What you do on either matters far more.
- Tirzepatide drives more total weight loss (20.2% vs 13.7% in the head-to-head SURMOUNT-5 trial), so even a similar lean mass fraction means comparable or greater absolute muscle lost.
- A large real-world preprint actually points to tirzepatide costing slightly more lean mass than semaglutide. Directional, not yet peer-reviewed.
- The pooled trial estimate puts lean loss near 25% of total weight for the class, with the two strongest agents the hardest on lean mass.
- Drug selection is the starting point. Protocol execution is where body composition is actually decided.
Both drugs produce meaningful fat loss. For someone focused on body composition, the question isn’t which causes more scale weight loss (the data on that is clear) but which produces a better ratio of fat loss to lean mass loss, and what that means for how you look and perform.
The honest answer: neither drug is clearly better for lean mass preservation once you account for total weight lost. The more important variable is what you do with either. If you want that “what you do” packaged as a protocol, the free GLP-1 Starter Framework is it. But the comparison is worth examining, because the distinction between percentage and absolute lean mass loss matters more than most coverage acknowledges.
The Mechanism Difference
Semaglutide is a GLP-1 monoagonist. It activates GLP-1 receptors in the pancreas, hypothalamus, brainstem, and elsewhere, producing appetite suppression, slowed gastric emptying, and improved glucose homeostasis.
Tirzepatide is a GIP/GLP-1 dual agonist. It activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP receptors are expressed in adipocytes, and preclinical data suggest GIP agonism may have direct lipolytic effects that could theoretically improve fat oxidation beyond GLP-1 alone. That’s the mechanistic basis for the hypothesis that tirzepatide might produce a more favorable body composition outcome relative to total weight lost.
The clinical data only partially supports that hypothesis, with important caveats.
The Body Composition Data, Both Drugs
The cleanest comparison of total weight loss now comes from a direct head-to-head trial rather than cross-trial guesswork. SURMOUNT-5 randomized 751 adults with obesity and without type 2 diabetes to tirzepatide or semaglutide for 72 weeks. Mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide (Aronne LJ et al. NEJM. 2025;doi:10.1056/NEJMoa2416394). That gap matters for the body composition question, even though SURMOUNT-5 measured weight and waist circumference rather than a DXA lean-versus-fat split.
For lean mass specifically, the most robust read comes from the pooled analysis of 22 randomized trials and 2,258 participants (Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Metabolism. 2025;164:156113), which put lean mass at approximately 25% of total weight lost across the class, and specifically flagged semaglutide 2.4 mg and tirzepatide 15 mg as the two agents least effective at preserving lean mass. The drugs that drive the most weight loss also tend to take the most lean tissue along the way. The full lean-mass picture across the trials covers the range, and the deeper STEP 1 breakdown goes through the semaglutide-specific numbers.
Here’s the number that actually matters in the comparison: because tirzepatide drives more total loss, a comparable lean mass fraction still means comparable or greater absolute lean tissue gone. A lower percentage of a much larger total is not a win for muscle.
A More Recent Real-World Signal
A large real-world analysis using EHR-linked body composition data, roughly 7,965 patients with paired pre- and post-treatment measurements, found tirzepatide associated with greater relative lean mass loss than semaglutide at every time point measured, with excess lean losses of about 1.1, 1.5, 1.3, and 2.0 percentage points at 3, 6, 9, and 12 months. Among patients losing more than 20% of body weight, a meaningful lean reduction was more common on tirzepatide than semaglutide.
Disclosure: this analysis remains a preprint as of mid-2026, not yet peer-reviewed (Murugadoss K et al., medRxiv, 2026). Treat it as directional supporting context, not established evidence. The finding is plausible given tirzepatide’s greater appetite suppression and weight loss, but it hasn’t been through peer review. If a peer-reviewed version exists by the time you read this, defer to it.
The Honest Comparison
The clinical data doesn’t clearly favor either drug for lean mass preservation when adjusted for total weight lost. The mechanism argument for tirzepatide’s adipose-direct effects is biologically plausible, but the absolute lean losses are comparable, and the real-world signal points toward tirzepatide users potentially losing more lean mass, likely because greater efficacy creates a more aggressive deficit and a harder protein and training problem.
Cost and access are real factors. Tirzepatide is generally more expensive, with variable coverage and telehealth availability. Semaglutide has a longer market history, more body composition data, and broader access.
I started on semaglutide. Cost was the deciding factor; tirzepatide wasn’t accessible to me at a price that made practical sense. Based on the body composition data, I don’t think that was a meaningful compromise. The lever that matters most isn’t which drug is in the syringe. It’s what you do while you’re on it.
What Matters More Than Which Drug You Choose
The lean mass numbers from the trials describe populations with no structured preservation strategy. They aren’t predictions about you. They’re baselines under default conditions, and the gap between those baselines and optimized outcomes is large.
A case series by Tinsley GM and Nadolsky S (Sage Open Med Cases. 2025) documented three GLP-1 users, including one on tirzepatide, training three to five days per week at 1.6–2.3 g protein per kg of fat-free mass. All three preserved or gained lean mass. Three people is a case series, not a trial, but it’s directionally consistent with the physiology.
The practical implication: a man on semaglutide who hits his protein target, trains at minimum effective volume, and manages his rate of loss will almost certainly produce better body composition than a man on tirzepatide who doesn’t, despite the dual agonist’s pharmacological edge. Drug selection is the starting point; the three levers are where outcomes are determined, and the full framework ties them together.
What the Emerging Agent Data Suggests
Two next-generation agents are worth watching, but this section requires a publish-day verification pass. Approval status, filing status, and trial readouts can change quickly in this category.
The body composition implication is the stable point: higher-efficacy drugs create larger total weight loss, and larger total loss makes protein, resistance training, and rate-of-loss control more important, not less.
As of the final publication check, retatrutide and CagriSema should be treated according to their current regulatory status, not remembered status from an earlier draft. If either remains investigational, say so plainly. If either has been approved, update this section with the approved indication, dose range, and source. Do not include expected approval timing unless it is sourced from the FDA, the sponsor, or a current regulatory filing.
The directional point from both: body composition at these efficacy levels will demand more deliberate lean mass preservation, not less. Greater weight loss magnitudes require proportionally greater attention to protein, training, and rate of loss. The three levers apply regardless of which drug you’re taking, or will be.
Get the Free GLP-1 Starter Framework
Download the free GLP-1 Starter Framework, the three-lever system for losing fat without losing muscle.
For the evidence behind the drug comparison and the body composition data, GLP-1 & Body Composition covers the trial findings, lean mass caveats, and how to interpret the semaglutide versus tirzepatide question without overreading the data.
FAQ
Is tirzepatide or semaglutide better for keeping muscle?
Neither is clearly better once you account for total weight lost. Tirzepatide produces more weight loss, so even a similar lean mass fraction means comparable or greater absolute muscle gone. The pooled trial data flags both top doses as the least effective at preserving lean mass, and a real-world preprint suggests tirzepatide may cost slightly more lean tissue. What you do (protein, training, rate of loss) matters far more than the choice between them.
Does tirzepatide cause more muscle loss than semaglutide?
Possibly, in absolute terms. Because tirzepatide drives greater total weight loss, more lean tissue tends to come along with it even at a similar percentage. A large real-world preprint found tirzepatide associated with about 1.1–2.0 percentage points more relative lean mass loss than semaglutide over 3–12 months, though that analysis isn’t yet peer-reviewed. The likely reason is mechanical: a steeper deficit makes the protein and training problem harder, not a unique catabolic effect.
Which GLP-1 is best for body composition?
There’s no clear pharmacological winner. The data doesn’t separate them meaningfully once total weight loss is accounted for. The best GLP-1 for your body composition is the one you can access and afford consistently, paired with a deliberate preservation protocol. A man on semaglutide doing the three levers will out-recomp a man on tirzepatide doing none of them. Pick on cost, access, and tolerability, then execute the protocol.
Does Mounjaro preserve muscle better than Ozempic?
Mounjaro (tirzepatide) doesn’t appear to preserve muscle better, and may preserve it slightly worse in absolute terms, because it drives more total weight loss. Its dual GIP/GLP-1 mechanism is theorized to favor fat loss, but the clinical and real-world data don’t show a lean mass preservation advantage over Ozempic (semaglutide). Both lose meaningful lean mass under default conditions, and both respond to the same protein, training, and rate-of-loss strategy.
Are retatrutide and CagriSema approved yet?
Approval status for emerging obesity drugs changes quickly, so this answer needs a final check before publishing. The safe rule is simple: if a drug is not FDA-approved for the relevant indication at the time of publication, treat it as investigational and not legally available by prescription outside clinical trials. For body composition, the practical point does not change: stronger weight-loss drugs require stronger lean mass protection, not less.
Nothing on this site constitutes medical advice. I’m not a physician, and this blog documents my own research and experience. Consult a qualified healthcare provider for decisions about medication, dosing, or treatment.
— Ryan Mercer | MetabolicMale.com | ryanmercer@metabolicmale.com
Citations:
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205-216.
Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM. 2025;doi:10.1056/NEJMoa2416394.
Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113.
Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. Sage Open Med Cases. 2025.
Murugadoss K et al. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping. medRxiv (preprint). 2026.
Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. NEJM. 2023;389:514-526.
